Cyrano Therapeutics

Washington, United States Founded: 2014 • Age: 12 yrs
Pharmaceutical therapies for smell and taste loss are developed.
Annual revenue - Latest available
Total funding $25.9M 4 rounds
Employees - Tracked headcount
Investors 4 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Cyrano Therapeutics

Cyrano Therapeutics is a company based in Washington (United States) founded in 2014. Cyrano Therapeutics has raised $25.88 million across 4 funding rounds from investors including Florida Opportunity Fund, Lumira Ventures and Remiges Ventures.

  • Headquarter Washington, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $25.88 M (USD)

    in 4 rounds

  • Latest Funding Round
    $9 M (USD), Series B

    Jan 16, 2024

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Cyrano Therapeutics

Headcount 1-10
Employee Profiles 4
Board Members and Advisors 3
Employee Profiles
People
Rick Geoffrion
Founder, President & CEO
People
R. I. Henkin
Co-Founder & Chief Scientific Advisor
People
Ron Kuppersmith
Chief Medical Advisor

Unlock access to complete

Board Members and Advisors
people
Taka Koda
Director
people
John Kollins
Director
people
Gerry Brunk
Director

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Cyrano Therapeutics

Cyrano Therapeutics has successfully raised a total of $25.88M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $9 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Cyrano Therapeutics

Cyrano Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Florida Opportunity Fund, Lumira Ventures and Remiges Ventures.

All
Venture Fund
Investor Description Founded Year Domain Location
Fund-of-funds and VC investor funding companies in the US
Locked Locked Locked
Lumira Ventures is engaged in life sciences venture capital investment.
Locked Locked Locked
Remiges Ventures is engaged in biotech venture capital investments.
Locked Locked Locked
Premium access

Investor details for Cyrano Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cyrano Therapeutics

Investments
Premium access

Investment portfolio details for Cyrano Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Cyrano Therapeutics

Premium access

Detailed financials for Cyrano Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cyrano Therapeutics Comparisons

Cyrano Therapeutics Primary company
Description
Pharmaceutical therapies for smell and taste loss are develo...
Location
Washington, United States
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Cyrano Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cyrano Therapeutics

Premium access

Detailed competitors of Cyrano Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cyrano Therapeutics

Premium access

Complete news archive for Cyrano Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cyrano Therapeutics

Cyrano Therapeutics was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Cyrano Therapeutics is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.

Cyrano Therapeutics is a funded company, having raised a total of $25.88M across 4 funding rounds to date.

Cyrano Therapeutics was founded in 2014 as a biotechnology firm focused on olfactory disorders. Pharmaceutical treatments for long-term smell and taste loss, including hyposmia, are developed through research into underlying causes of dysfunction. Clinical trials are conducted to assess therapy safety and efficacy, with operations centered on restoring sensory function for affected patients.

Cyrano Therapeutics has 4 investors. Key investors include Florida Opportunity Fund, Lumira Ventures, Remiges Ventures, and DORAHOKI.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available